Zaporožskij Medicinskij Žurnal (Feb 2017)

Clinical effectiveness of exogenous L-arginine in patients with coronary heart disease after community-acquired pneumonia

  • T. O. Kulynych

DOI
https://doi.org/10.14739/2310-1210.2017.1.91601
Journal volume & issue
no. 1
pp. 9 – 13

Abstract

Read online

Coronary heart disease and community acquired pneumonia associated with a higher risk for morbidity and mortality. The optimization of treatment of comorbid pathology by medicines which modify endothelium functional state is important. Aim: to study effect of exogenous L-arginine on clinical course of disease, markers of systemic inflammation and endothelial dysfunction in patients with coronary heart disease (CHD) and community-acquired pneumonia (CAP). Materials and methods. 60 patients with CHD and CAP (the median 72.50 years, range 66.00; 75.00) were included into the study. Patients were randomized in 2 groups: first – 30 patients with basic therapy combined with L-arginine; and second – 30 patients with basic therapy. hs-CRP, neopterin, РАРР-А, NT-proBNP were measured by ELISA-TEST before treatment and 1 month after. Clinical course was assessed during 1 year of follow-up. Results. In the first group the hospitalization rate due to CHD and heart failure decompensation was significantly rare. Biomarkers changes in the 1st group were significant: hs-CRP was significantly decreased by 57.14 % (in the 2nd group – by 28.57 %); neopterin – by 36.57 % (in the 2nd group – by 20.91 %); РАРР-А – by 35.71 % (in the 2nd group – by 4.76 %). There was revealed a significant decreasing of NT-proBNP levels in patients receiving L-arginine by comparing with basic therapy: with the I stage of heart failure (HF) – by 50.97 % vs 21.82 %, with the II-A stage of HF – by 43.82 % vs 5.61 % (p < 0.05). After 1 month of therapy patients from the 1st group had significantly lower rates of neopterin – by 16.46 %, and NT-proBNP – by 40.92 % in the subgroup of patients with II-A stage of HF (p < 0.05) compared with patients who received only the basic therapy. Conclusions. Combination of exogenous L-arginine and basic therapy in patients with CHD and CAP was associated with benign clinical course and positive changes of endothelium functional state, immune and inflammation activation.

Keywords